Skip to main content

Table 1 Baseline characteristics of included studies and all-cause mortality (binary data)

From: Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis

     

Baseline characteristics

All-cause mortality (binary)

References

Trial

Treatment

Dose

Study duration (weeks)

n

Mean age (yr.)

Women (%)

Current smokers (%)

FEV1 (mean % predicted)

Subjects

Deaths - ITT

Deaths – OT

[53]

Aaron 2007

Tiotropium + Salmeterol

18 μg od/50 μg bid

52

148

67.6

42.6

24.3

41.2

148

6

NR

Tiotropium + SFC

18 μg od/50/500 μg bid

 

145

67.5

42.1

32.4

42.2

145

6

NR

Tiotropium + Placebo

18 μg od

 

156

68.1

46.2

26.9

42.1

156

4

NR

[40]

Anzueto 2009

SFC

50/250 μg bid

52

394

65.4

49.0

42.0

41.2

394

4

NR

Salmeterol

50 μg bid

 

403

65.3

43.0

43.0

40.0

403

6

NR

[54]

Bateman 2010

Tiotropium

5 μg od

48

1952

64.8

21.9

35.7

45.2

1952

52

NR

Placebo

-

 

1965

64.8

23.0

35.9

45.4

1965

38

NR

[55]

ISOLDE (Burge 2000)

Fluticasone Propionate

500 μg bid

156

376

63.7

25.0

36.4

50.3

372

32

NR

Placebo

-

 

375

63.8

26.0

39.2

50.0

370

36

NR

[56]

Calverley 2003

Budesonide + Formoterol

320/9 μg bid

52

254

64.0

22.0

33.0

36.0

254

5

NR

Budesonide

400 μg bid

 

257

64.0

26.0

39.0

36.0

257

6

NR

Formoterol

9 μg bid

 

255

63.0

25.0

36.0

36.0

255

13

NR

Placebo

-

 

256

65.0

25.0

30.0

36.0

256

5

NR

[5]

TORCH* (Calverley 2007)

Fluticasone Propionate

500 μg bid

156

1534

65.0

25.0

43.0

44.1

1534

246

NR

Salmeterol

50 μg bid

 

1521

65.1

24.0

43.0

43.6

1521

205

NR

SFC

50/500 μg bid

 

1533

65.0

25.0

43.0

44.3

1533

193

NR

Placebo

-

 

1524

65.0

24.0

43.0

44.1

1524

231

NR

[57]

Calverley 2007

Roflumilast

500 μg od

52

760

65.0

25.0

38.0

41.0

760

12

NR

Placebo

  

753

64.0

24.0

35.0

41.0

753

20

NR

[58]

M2-124 (Calverley 2009)

Roflumilast

500 μg od

52

765

64.0

29.0

48.0

37.6

765

17

NR

Placebo

  

758

63.0

29.0

48.0

37.5

758

17

NR

M2-125 (Calverley 2009)

Roflumilast

500 μg od

52

772

64.0

21.0

35.0

34.6

772

25

NR

 

Placebo

  

796

64.0

19.0

35.0

35.3

796

25

NR

[59]

Calverley 2010

Beclomethasone + Formoterol

200/12μg bid

48

232

63.0

20.7

38.8

41.9a

232

2

NR

Budesonide + Formoterol

400/12μg bid

 

238

64.1

18.5

36.1

42.3a

238

4

NR

Formoterol

12 μg bid

 

233

63.7

18.9

37.3

42.5a

233

0

NR

[49]

Campbell 2005

Formoterol bid + Formoterol

9 μg bid / 4.5 μg as needed

26

225

60.0

29.0

56.0

54.4b

225

1

NR

Formoterol bid + Terbutaline

9μg bid / 0.5 mg as needed

 

215

60.0

39.0

54.0

53.0b

215

2

NR

Placebo + Terbutaline

0.5 mg as needed

 

217

60.0

27.0

55.0

54.1b

217

0

NR

[26]

Casaburi 2005

Tiotropium

18 μg od

25

55

65.9

45.5

29.1

32.6b

55

1

NR

Placebo

-

 

53

67.3

41.5

18.9

36.2b

53

0

NR

[27]

Chan 2007

Tiotropium

18 μg od

48

608

66.8

41.0

32.0

39.4b

608

15

13

 

Placebo

-

 

305

66.9

39.0

30.0

39.3b

305

4

2

[60]

Choudhury 2007

Fluticasone Propionate

500 μg bid

52

128

67.6

52.0

40.6

53.2

128

3

NR

Placebo

-

 

132

67.3

44.0

35.6

55.0

132

0

NR

[28]

INVOLVE (Dahl 2010)

Indacaterol (300)

300μg od

52

437

64.0

19.7

NR

51.5

437

1

1

Indacaterol (600)

600μg od

 

425

63.0

23.1

NR

50.8

428

1

0

Formoterol

12μg (bid)

 

434

64.0

19.8

NR

52.5

435

5

3

Placebo

-

 

432

63.0

18.5

NR

52.0

432

5

4

[29]

Donohue 2002

Salmeterol

50 μg bid

26

213

64.6

25.0

NR

40.2bc

213

3

NR

Tiotropium

18 μg od

 

209

64.5

26.0

NR

40.2bc

209

0

NR

Placebo

-

 

201

65.6

25.0

NR

40.2bc

201

4

NR

[30]

INHANCE (Donohue 2010)

Indacaterol (150)

150 μg od

26

416

63.4

37.7

NR

56.1

416

1

NR

Indacaterol (300)

300 μg od

 

416

63.3

36.8

NR

56.3

416

0

NR

Tiotropium

18 μg od

 

415

64.0

35.2

NR

53.9

415

2

NR

Placebo

-

 

418

63.6

39.0

NR

56.1

418

0

NR

[31]

Ferguson 2008

SFC

250/50 μg bid

52

394

64.9

42.0

40.0

39.8

394

6

NR

Salmeterol

50 μg bid

 

388

65.0

48.0

38.0

40.6

388

3

NR

[32]

Hanania 2003

Fluticasone Propionate

250 μg bid

24

183

63.0

34.0

48.0

42.0b

183

0

NR

Salmeterol

50 μg bid

 

177

64.0

42.0

51.0

42.0

177

0

NR

SFC

250 / 50 μg bid

 

178

63.0

39.0

43.0

41.0

178

0

NR

Placebo

-

 

185

65.0

32.0

47.0

42.0b

185

0

NR

[33]

VIVACE (Kardos 2007)

Salmeterol

50 μg bid

44

487

64.0

22.4

44.4

40.3

487

9

NR

SFC

50/500 μg bid

 

507

63.8

26.0

40.6

40.4

507

7

NR

[41]

Kerstjens 1992

Ipratropium Bromide + Terbutaline

800/2000 μg bid

130

92

38.9

36.0

34.0

63.3a

92

0

NR

Beclomethasone + Terbutaline

160/2000 μg bid

 

91

40.2

35.0

36.0

64.6a

91

0

NR

Placebo + Terbutaline

na/2000 μg bid

 

91

39.6

36.0

37.0

63.3a

91

0

NR

[42]

INLIGHT-2 (Kornmann 2011)

Indacaterol

150 μg od

26

330

63.0

28.0

46.0

54.0

330

1

NR

Salmeterol

50 μg bid

 

333

63.0

25.0

46.0

53.0

333

0

NR

Placebo

-

 

335

64.0

23.0

45.0

53.0

335

3

NR

[34]

Mahler 2002

Fluticasone Propionate

500 μg bid

24

168

64.4

39.0

46.0

41.0b

168

0

NR

Salmeterol

50 μg bid

 

160

63.5

36.0

46.0

40.0b

160

0

NR

SFC

50 / 500 μg bid

 

165

61.9

38.0

46.0

41.0b

165

0

NR

Placebo

-

 

181

64.0

25.0

54.0

41.0b

181

3

NR

[61]

Niewoehner 2005

Tiotropium

-

26

914

67.6

2.0

29.0

35.6b

914

22

NR

Placebo

18 μg od

 

915

68.1

1.0

30.0

35.6b

915

19

NR

[22]

EUROSCOP (Pauwels 1999)

Budesonide

400μg bid

156

634

52.5

26.5

100.0

76.8a

634

8

NR

Placebo

-

 

643

52.4

27.8

100.0

76.9a

643

10

NR

[35]

Rennard 2009

Budesonide + Formoterol

320/9 μg bid

52

494

63.2

37.7

39.1

38.6

494

8

3

Budesonide + Formoterol

160/9 μg bid

 

494

63.6

37.2

41.9

39.6

494

8

6

Formoterol

9 μg bid

 

495

62.9

34.7

45.1

39.3

495

6

2

Placebo

-

 

481

62.9

34.7

43.9

40.8

481

8

4

[36]

FICOPD II (Rossi 2002)

Formoterol 12

12 μg bid

52

211

63.0

13.0

NR

47.0b

211

3

NR

Formoterol 24

24 μg bid

 

214

62.0

17.0

NR

47.0b

214

1

NR

Theophylline

200/300 mg bid

 

209

64.0

18.0

NR

46.0b

209

0

NR

Placebo

-

 

220

63.0

21.0

NR

49.0b

220

0

NR

[62]

Schermer 2009

Fluticasone Propionate

500 μg bid

156

94

58.4

27.0

62.0

68.7b

94

8

NR

Placebo

-

 

96

59.6

32.0

51.0

71.4b

96

3

NR

[23]

Shaker 2009

Budesonide

400 μg bid

208

127

63.6

38.0

100.0

51.0b

127

5

NR

Placebo

-

 

127

63.6

46.0

100.0

53.0b

127

5

NR

[43]

Stockley 2006

Salmeterol

50 μg bid

52

318

62.3

24.0

46.0

45.8b

216

6

NR

Placebo

-

 

316

62.4

23.0

47.0

46.1b

222

5

NR

[37]

Szafranski 2003

Budesonide + Formoterol

320/9 μg bid

52

208

64.0

24.0

30.0

36.0b

208

6

NR

Budesonide

400 μg bid

 

198

64.0

20.0

36.0

37.0b

198

5

NR

Formoterol

9 μg bid

 

201

63.0

24.0

38.0

36.0b

201

6

NR

Placebo

-

 

205

65.0

17.0

34.0

36.0b

205

9

NR

[63]

Tashkin 2008

Budesonide + Formoterol

320/9 μg bid

26

277

63.1

32.1

44.4

39.1

277

3

NR

Budesonide + Formoterol

160/9 μg bid

 

281

63.6

35.6

44.8

39.9

281

4

NR

Budesonide + Formoterol

320 + 9 μg bid (separate)

 

287

63.7

25.8

41.5

39.2

287

0

NR

Budesonide

320 μg bid

 

275

63.4

32.4

42.9

39.7

275

2

NR

Formoterol

9 μg bid

 

284

63.5

34.5

41.9

39.6

284

1

NR

Placebo

-

 

300

63.2

31.0

39.7

41.3

300

1

NR

[64, 65]

UPLIFT (Tashkin 2008/Celli 2009)

Tiotropium

18 μg od

208

2986

64.5

24.6

29.3

47.7

2987

446

381

Placebo

-

 

3006

64.5

26.1

29.9

47.4

3006

495

411

[44]

Tonnel 2008

Tiotropium

18 μg od

39

266

64.9

13.2

23.7

47.5b

266

3

NR

Placebo

  

288

63.5

14.6

30.2

46.2b

288

6

NR

[45]

COPE (van der Valk 2002)

Fluticasone Propionate

500 μg bid

26

123

64.1

14.6

22.0

57.5

123

1

NR

Placebo

-

 

121

64.0

16.5

33.3

56.1

121

1

NR

[46]

CCLS (Vestbo 1999)

Budesonide

800 μg od + 400 μg od for 6 months; 400 μg bid for 30 month

156

145

59.0

41.4

75.9

86.2

145

4

NR

Placebo

-

 

145

59.1

37.9

77.2

86.9

145

5

NR

[38]

Vogelmeier 2008

Formoterol

10 μg bid

24

210

61.8

24.3

NR

51.6b

210

0

NR

Tiotropium

18 μg od

 

221

63.4

20.8

NR

51.6b

221

0

NR

Tiotropium + Formoterol

18 μg od/10 μg bid

 

207

62.6

20.8

NR

50.4

207

0

NR

Placebo

-

 

209

62.5

22.5

NR

51.1

209

1

NR

[47]

POET-COPD 2011 (Vogelmeier 2011)

Tiotropium

18 μg od

52

3707

62.9

25.6

48.0

49.2

3707

64

66

Salmeterol

50 μg bid

 

3669

62.8

25.1

48.3

49.4

3669

78

73

[66]

INSPIRE (Wedzicha 2008)

SFC

50/500 μg bid

104

658

64.0

19.0

38.0

39.1

658

21

18

Tiotropium

18 μg od

 

665

65.0

16.0

38.0

39.4

665

38

34

[24]

LHS (Wise 2000)

Triamcinolone

600 μg bid

156

559

56.2

36.0

90.5

68.5

559

15

NR

Placebo

-

 

557

56.4

37.9

89.8

67.2

557

19

NR

[39]

Zheng 2007

SFC

50/500 μg bid

24

297

66.0

9.4

21.0

47.0b

297

2

NR

Placebo

-

 

148

66.6

13.5

23.0

47.0b

148

0

NR

[48]

Zhong 2012

Budesonide + Formoterol

320/9 μg bid

26

156

65.7

1.9

NR

36.2

156

1

NR

Budesonide

400 μg bid

 

152

64.7

7.9

NR

36.3

152

0

NR

  1. FEV1 – mean % predicted, post-bronchodilator
  2. *Powered to detect mortality
  3. aMean % predicted FEV1 is pre-bronchodilator
  4. bNot stated whether mean % predicted FEV1 is pre-bronchodilator or post-bronchodilator
  5. cFEV1 is mean of the three treatment arms